PHILADELPHIA — Lannett Co. has been cleared by the Food and Drug Administration to market for butalbital, acetaminophen and caffeine tablets (50mg/325mg/40mg).
The company said Friday that the combination product, slated to begin shipping next month, is a generic version of Fioricet.
The medication is indicated for the treatment of tension headaches caused by muscle contractions.
"Sales of butalbital, acetaminophen and caffeine tablets have been climbing 5% annually over the past three years," stated Arthur Bedrosian, president and chief executive officer of Lannett. "This approval continues the positive momentum we have generated over the last several quarters."
Overall sales of butalbital, acetaminophen and caffeine tablets were about $30 million, of which about $15 million was for the Fioricet branded version, according to IMS Health figures reported by Lannett.
